Pro-inflammatory and anti-inflammatory interleukins in infectious diseases: A comprehensive review

AA Al-Qahtani, FS Alhamlan, AA Al-Qahtani - Tropical medicine and …, 2024 - mdpi.com
Interleukins (ILs) are signaling molecules that are crucial in regulating immune responses
during infectious diseases. Pro-inflammatory ILs contribute to the activation and recruitment …

COVID-19: breaking down a global health crisis

SI Mallah, OK Ghorab, S Al-Salmi, OS Abdellatif… - Annals of clinical …, 2021 - Springer
Abstract Coronavirus disease 2019 (COVID-19) is the second pandemic of the twenty-first
century, with over one-hundred million infections and over two million deaths to date. It is a …

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label …

CC Butler, FDR Hobbs, OA Gbinigie, NM Rahman… - The Lancet, 2023 - thelancet.com
Background The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …

[HTML][HTML] Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform …

G Reis, EA dos Santos Moreira-Silva… - The Lancet Global …, 2022 - thelancet.com
Background Recent evidence indicates a potential therapeutic role of fluvoxamine for
COVID-19. In the TOGETHER trial for acutely symptomatic patients with COVID-19, we …

[HTML][HTML] COVID-19-neutralizing antibodies predict disease severity and survival

WF Garcia-Beltran, EC Lam, MG Astudillo, D Yang… - Cell, 2021 - cell.com
Summary Coronavirus disease 2019 (COVID-19) exhibits variable symptom severity ranging
from asymptomatic to life-threatening, yet the relationship between severity and the humoral …

Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial

DC Angus, L Derde, F Al-Beidh, D Annane, Y Arabi… - Jama, 2020 - jamanetwork.com
Importance Evidence regarding corticosteroid use for severe coronavirus disease 2019
(COVID-19) is limited. Objective To determine whether hydrocortisone improves outcome for …

A living WHO guideline on drugs for covid-19

A Agarwal, BJ Hunt, M Stegemann, B Rochwerg… - bmj, 2020 - bmj.com
Updates This is the fourteenth version (thirteenth update) of the living guideline, replacing
earlier versions (available as data supplements). New recommendations will be published …

COVID-19 transmission, current treatment, and future therapeutic strategies

VS Salian, JA Wright, PT Vedell, S Nair… - Molecular …, 2021 - ACS Publications
At the stroke of the New Year 2020, COVID-19, a zoonotic disease that would turn into a
global pandemic, was identified in the Chinese city of Wuhan. Although unique in its …

Effect of early treatment with ivermectin among patients with Covid-19

G Reis, EASM Silva, DCM Silva… - … England Journal of …, 2022 - Mass Medical Soc
Background The efficacy of ivermectin in preventing hospitalization or extended observation
in an emergency setting among outpatients with acutely symptomatic coronavirus disease …

[PDF][PDF] A living WHO guideline on drugs for covid-19

F Lamontagne, T Agoritsas, H Macdonald, YS Leo… - bmj, 2020 - zyicu.cn
The evidence base for therapeutics for covid-19 is evolving with numerous randomised
controlled trials (RCTs) recently completed and under way. This update adds new …